Evidence map›Paper›PMID 41302616›Full record

ArticleInternational journal of environmental research and public health2025

A Bibliometric Analysis of the HCV Drug-Resistant Majority and Minority Variants.

Omega Mathew Immanuel, Olaoluwa Tolulope Fabiyi, Kuat P Oshakbayev, Gulzhan Abuova, Aliya Konysbekova, Sreenu B Vattipally, Syed Ali, Syed Hani Abidi

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Omega Mathew ImmanuelDepartment of Biomedical Sciences, Nazarbayev University School of Medicine, Astana 010000, Kazakhstan.ORCID 0000-0002-4714-5069
Olaoluwa Tolulope FabiyiDepartment of Biomedical Sciences, Nazarbayev University School of Medicine, Astana 010000, Kazakhstan.
Kuat P OshakbayevUniversity Medical Center, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0003-4883-295X
Gulzhan AbuovaDepartment of Infectious Diseases and Dermatovenereology, South Kazakhstan Medical Academy, Shymkent 160019, Kazakhstan.ORCID 0000-0002-1210-2018
Aliya KonysbekovaClinic of Hepatology, Gastroenterology and Nutrition, Astana 010000, Kazakhstan.ORCID 0009-0002-4841-5056
Sreenu B VattipallyMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow G61 1QH, UK.ORCID 0000-0001-6673-4697
Syed AliDepartment of Biomedical Sciences, Nazarbayev University School of Medicine, Astana 010000, Kazakhstan.
Syed Hani AbidiDepartment of Biomedical Sciences, Nazarbayev University School of Medicine, Astana 010000, Kazakhstan.ORCID 0000-0001-9497-0902

Funding

Molecular Virology/Epidemiology HIV Training in Kazakhstan (MoVE-Kaz)D43TW012507 · FIC · YALE UNIVERSITY · PI STEN H. VERMUND · 2023 to 2026
$1.2M
FIC NIH HHS D43 TW012507Nazarbayev University Collaborative Research Program Grant 111024CRP2013
6 · The paper itself

Abstract

backgroundIn recent decades, research on Hepatitis C Virus (HCV) drug-resistant variants has expanded; however, critical gaps remain in our understanding of global contributions, emerging trends, and future research directions. Here, we present a bibliometric analysis to understand the research themes and trends in research related to HCV drug-resistant variants published between 1999 and 2025.

methodsPublications related to HCV drug-resistant variants published between 1999 and 2025 were searched on the Web of Science and Scopus databases. Publication metadata and content-based data were extracted and analyzed using Bibliometrix and VOSviewer for keyword co-occurrence plot and cluster analysis.

resultsThe analysis of 653 articles revealed a clear paradigm shift, driven by the introduction of direct-acting antivirals (DAAs), which led to a significant surge in annual publications, peaking between 2014 and 2018. This shift in focus led to an emphasis on DAA efficacy, resistance mechanisms, and advanced genotyping. The United States was the most productive country, with the highest number of publications (

conclusionsThe field successfully transitioned to the DAA era, but research output and collaboration networks were primarily driven by high-income countries, leaving a critical gap in data from Low- and Middle-Income Countries (LMICs). Closing this gap by integrating LMIC data is the next essential step to ensure global elimination strategies are effective for all countries from different income strata.

Indexed as

Antiviral AgentsBibliometricsDrug Resistance, ViralHepacivirusHepatitis CHumansAntiviral AgentsDAAsdrug-resistant variantsHCVinterferonmutationnext-generationsequencing

Identifiers

PMID41302616
PMCPMC12652138

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.